Gensaic Partners with Novo Nordisk to Advance Next-Gen Precision Therapies Gensaic, Inc., a pioneering biotechnology company leveraging AI-driven protein design and biological insights to develop precision ligands for targeted drug…
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, has unveiled promising preclinical data on SOT109, a next-generation antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). These findings reinforce the strong…
Revvity’s EUROIMMUN Secures CE Mark for Innovative Measles Antibody Test Revvity, Inc. (NYSE: RVTY) has announced the launch of EUROIMMUN’s Anti-Measles Virus ELISA 2.0 (IgG), which has received the CE…
Surescripts 2024 Annual Impact Report Highlights Surge in Health Intelligence Sharing, Enhancing Care Quality & Access Surescripts, the nation’s leading health information network, has released its highly anticipated 2024 Annual…
LabVantage Solutions Unveils LIMS 8.9: Transforming Lab Productivity and Efficiency LabVantage Solutions, Inc., a global leader in laboratory informatics, has announced the launch of LabVantage 8.9, the latest evolution of…
Tenovi and GenieMD Partner to Revolutionize Remote Care and Improve Medication Adherence GenieMD and Tenovi have announced a groundbreaking partnership aimed at expanding access to remote care and improving medication…
Repare Therapeutics Shares Business, Clinical Update & 2024 Financial Results Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, has released its financial results for…
Protagonist and Takeda Announce Positive Phase 3 VERIFY Study Results for Rusfertide in Polycythemia Vera Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ: PTGX) and Takeda (TSE: 4502/NYSE: TAK) have announced positive topline…
Guardian Pharmacy Services Reports Preliminary Q4 and Full-Year 2024 Results, Provides 2025 Guidance Guardian Pharmacy Services, Inc. (“Guardian” or the “Company”) (NYSE: GRDN), one of the largest long-term care (LTC)…
Celltrion Secures EC Approval for Avtozma® (CT-P47), a Biosimilar to RoActemra® Celltrion has announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a biosimilar referencing RoActemra®…
QIAGEN Takes Legal Action to Defend QuantiFERON Intellectual Property and Protect Innovations in Latent Tuberculosis Testing QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has filed a patent infringement complaint…
SmithRx Adds Stelara Biosimilars, Projecting $14.5M Savings SmithRx, a transparent and fully pass-through modern pharmacy benefits manager (PBM), has announced a significant expansion of its Connect 360 Autoimmune Program. This…
